Anja Ussing

Anja Ussing

Auto-generated profile, based on publicly available information

Anja Ussing

The Danish Health Authority, 2300, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2023 in eClinicalMedicine
Verified
Journal Article
Open access
Mina HändelMina Händel
Mina Händel
HAHenning Keinke Andersen
Henning Keinke Andersen
AUAnja Ussing
Anja Ussing
AVAnne Virring
Anne Virring
PJPoul Jennum
Poul Jennum
HCHenriette Edemann Callesen
Henriette Edemann Callesen
Currently, melatonin is used to treat children and adolescents with insomnia without knowing the full extent of the short-term and long-term consequences. Our aim was to provide clinicians and guideline panels with a systematic assessment of serious—and non-serious adverse events seen in continuation of melatonin treatment and the impact on pubertal development and bone health following long-term administration in children and adolescents with chronic insomnia. We searched PubMed, Embase, Cinahl and PsycINFO via Ovid, up to March 17, 2023, for studies on melatonin treatment among children and adolescents (aged 5–20 years) with chronic insomnia. The language was restricted to English, Danish, Norwegian, and Swedish. Outcomes were non-serious adverse events and serious adverse events assessed 2–4 weeks after initiating treatment and pubertal development and bone health, with no restriction on definition or time of measurement. Observational studies were included for the assessment of long-term outcomes, and serious and non-serious adverse events were assessed via randomised studies. The certainty of the evidence was assessed using Grades of Recommendation, Assessment, Development and Evaluation (GRADE). The protocol is registered with the Danish Health Authority. We identified 22 randomised studies with 1350 patients reporting on serious—and non-serious adverse events and four observational studies with a total of 105 patients reporting on pubertal development. Melatonin was not associated with serious adverse events, yet the number of patients experiencing non-serious adverse events was increased (Relative risk 1.56, 95% CI 1.01–2.43, 17 studies, I2 = 47%). Three studies reported little or no influence on pubertal development following 2–4 years of treatment, whereas one study registered a potential delay following longer treatment durations (>7 years). These findings need further evaluation due to several methodological limitations. Children who use melatonin are likely to experience non-serious adverse events, yet the actual extent to which melatonin leads to non-serious adverse events and the long-term consequences remain uncertain. This major gap of knowledge on safety calls for caution against complacent use of melatonin in children and adolescents with chronic insomnia and for more research to inform clinicians and guideline panels on this key issue. The Danish Health Authority. The 10.13039/100014547 Parker Institute , Bispebjerg and Frederiksberg Hospital, supported by the 10.13039/100001275 Oak Foundation .

1 December 2021 in Archives of Physical Medicine and Rehabilitation
Verified
Journal Article
Open access
BLBehnam Liaghat
Behnam Liaghat
AUAnja Ussing
Anja Ussing
BPBirgitte Holm Petersen
Birgitte Holm Petersen
HAHenning Keinke Andersen
Henning Keinke Andersen
KBKristoffer Barfod
Kristoffer Barfod
SBStig Brorson
Stig Brorson
To study the effects of supervised training in adults with subacromial pain syndrome. EMBASE, MEDLINE, Cochrane Library, Cinahl, and Pedro were searched from inception to March 2020. Independent reviewers selected randomised controlled trials comparing supervised training with a) no training or b) self-training in adults with subacromial pain syndrome lasting for at least one month. Critical outcomes were shoulder pain, function, and patient-perceived effect. Important outcomes included other potential benefits and adverse events at three-month follow up. Two independent reviewers extracted data for the meta-analysis. Risk of bias was assessed using the Cochrane Risk of Bias tool 1, and certainty of evidence was evaluated using GRADE. Ten studies (n=597, 43% females) were included. Supervised training resulted in larger improvements than no training on pain (at rest: n=286; mean difference (MD) 1.68, 95% Confidence Interval (CI) 0.31, 3.06 on 0-10 scale; during movement: n = 353; MD 1.84, 95% CI 0.91, 2.76), function (n=396; standardized MD 0.30, 95% CI 0.07, 0.52), and patient-perceived effect (n=118; risk ratio 1.43, 95% CI 0.87, 2.34). Supervised training had potential benefits regarding quality of life, return to work, dropout, and training adherence, albeit more patients reported mild, transient pain following training. Supervised training and self-training showed equal improvements on pain (n = 44) and function (n = 76), with no data describing patient-perceived effect. Certainty of evidence was low for critical outcomes, and low-moderate for other outcomes. Supervised training might be superior to no training and equally effective as self-training on critical and important outcomes. Based on low-moderate certainty of evidence, these findings support a weak recommendation for supervised training in adults with subacromial pain syndrome.

1 October 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
AUAnja Ussing
Anja Ussing
IDInge Dahn
Inge Dahn
UDUlla Due
Ulla Due
MSMichael Sørensen
Michael Sørensen
JPJanne Petersen
Janne Petersen
TBThomas Bandholm
Thomas Bandholm
Pelvic floor muscle training (PFMT) in combination with conservative treatment is recommended as first-line treatment for patients with fecal incontinence, although its efficacy is unclear. We investigated whether supervised PFMT in combination with conservative treatment is superior to attention-control massage treatment and conservative treatment in adults with fecal incontinence. We performed a randomized, controlled, superiority trial of patients with fecal incontinence at a tertiary care center at a public hospital in Denmark. Ninety-eight adults with fecal incontinence were randomly assigned to groups that received supervised PFMT and biofeedback plus conservative treatment or attention-control treatment plus conservative treatment. The primary outcome was rating of symptom changes, after 16 weeks, based on scores from the Patient Global Impression of Improvement scale. Secondary outcomes were changes in the Vaizey incontinence score (Vaizey Score), Fecal Incontinence Severity Index, and Fecal Incontinence Quality of Life Scale. In the intention-to-treat analysis, participants in the PFMT group were significantly more likely to report improvement in incontinence symptoms based on Patient Global Impression of Improvement scale scores (unadjusted odds ratio, 5.16; 95% CI, 2.18-12.19; P = .0002). The PFMT group had a larger reduction in the mean Vaizey Score (reduction, -1.83 points; 95% CI, -3.57 to -0.08; P = .04). There were no significant differences in condition-specific quality of life. In the per-protocol analyses, the superiority of PFMT was increased. No adverse events were reported. This randomized controlled trial of adults with fecal incontinence provides support for a superior effect of supervised PFMT in combination with conservative treatment compared with attention-control massage treatment and conservative treatment. We found that participants who received supervised PFMT had 5-fold higher odds of reporting improvements in fecal incontinence symptoms and had a larger mean reduction of incontinence severity based on the Vaizey Score compared with attention control massage treatment. Clinicaltrials.gov no: NCT01705535.

6 September 2021 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Open access
PDF file
AUAnja Ussing
Anja Ussing
MMMarie-Louise Kirkegaard Mikkelsen
Marie-Louise Kirkegaard Mikkelsen
BVBrigitta Rasmussen Villumsen
Brigitta Rasmussen Villumsen
JWJohnny Wejlgaard
Johnny Wejlgaard
PBPernille Envold Bistrup
Pernille Envold Bistrup
TBThomas Bandholm
Thomas Bandholm
Background: Androgen deprivation therapy (ADT) in patients with prostate cancer can have several debilitating side effects. Supervised exercise is recommended to ameliorate these negative effects. Objective: To systematically evaluate the effect of supervised exercise therapy compared to no exercise therapy in patients with prostate cancer undergoing ADT, primarily according to the patient critical outcomes, ‘disease-specific quality of life’ and ‘walking performance’ measured at end of treatment. Methods: We searched PubMed/Medline, Embase, Cochrane Library, Cinahl and Pedro, to identify randomised controlled trials (RCTs), which investigated the effect of supervised exercise therapy compared to no exercise therapy in patients with prostate cancer receiving ADT, last search: June 2021. Two independent reviewers extracted data, and assessed risk of bias using Cochrane Risk of Bias Tool and evaluated the certainty of evidence using the GRADE-method. Results: Eigthteen RCTs (n = 1477) comprised patients with prostate cancer stages T1-T4 were included in the meta-analyses. Compared to no exercise therapy, supervised exercise therapy showed clinically relevant improvements in ‘disease-specific quality of life’ and ‘walking performance’. The standardised mean differences were 0.43 (95% confidence interval (CI): 0.29, 0.58) and −0.41 (95% CI: −0.60, −0.22), respectively. The overall certainty of evidence was moderate due to serious risk of bias. Conclusions: Evidence of moderate quality shows that supervised exercise therapy probably is superior to no exercise therapy in improving ‘disease-specific quality of life’ and ‘walking performance’ in patients with prostate cancer undergoing ADT. The results apply to all patients receiving androgen deprivation therapy regardless of cancer stage. The results support a strong recommendation for supervised exercise therapy for managing side effects in this population. Protocol registration: NKR-38-Focused-questions-PICOs-for-updating1.ashx (sst.dk)

CKChristoffer Bruun Korfitsen
Christoffer Bruun Korfitsen
MMMarie-Louise Kirkegaard Mikkelsen
Marie-Louise Kirkegaard Mikkelsen
AUAnja Ussing
Anja Ussing
KWKaren Christina Walker
Karen Christina Walker
JRJeanett Friis Rohde
Jeanett Friis Rohde
Mina HändelMina Händel
Mina Händel
The Danish Health Authority develops clinical practice guidelines to support clinical decision-making based on the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system and prioritizes using Cochrane reviews. The objective of this study was to explore the usefulness of Cochrane reviews as a source of evidence in the development of clinical recommendations. Evidence-based recommendations in guidelines published by the Danish Health Authority between 2014 and 2021 were reviewed. For each recommendation, it was noted if and how Cochrane reviews were utilized. In total, 374 evidence-based recommendations and 211 expert consensus recommendations were published between 2014 and 2021. Of the 374 evidence-based recommendations, 106 included evidence from Cochrane reviews. In 28 recommendations, all critical and important outcomes included evidence from Cochrane reviews. In 36 recommendations, a minimum of all critical outcomes included evidence from Cochrane reviews, but not all important outcomes. In 33 recommendations, some but not all critical outcomes included evidence from Cochrane reviews. Finally, in nine recommendations, some of the important outcomes included evidence from Cochrane reviews. In almost one-third of the evidence-based recommendations, Cochrane reviews were used to inform clinical recommendations. This evaluation should inform future evaluations of Cochrane review uptake in clinical practice guidelines concerning outcomes important for clinical decision-making.

1 December 2017 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
AUAnja Ussing
Anja Ussing
IDInge Dahn
Inge Dahn
UDUlla Due
Ulla Due
MSMichael Sørensen
Michael Sørensen
JPJanne Petersen
Janne Petersen
TBThomas Bandholm
Thomas Bandholm
Faecal incontinence affects approximately 8–9% of the adult population. The condition is surrounded by taboo; it can have a devastating impact on quality of life and lead to major limitations in daily life. Pelvic floor muscle training in combination with information and fibre supplements is recommended as first-line treatment for faecal incontinence. Despite this, the effect of pelvic floor muscle training for faecal incontinence is unclear. No previous trials have investigated the efficacy of supervised pelvic floor muscle training in combination with conservative treatment and compared this to an attention-control massage treatment including conservative treatment. The aim of this trial is to investigate if 16 weeks of supervised pelvic floor muscle training in combination with conservative treatment is superior to attention-control massage treatment and conservative treatment in patients with faecal incontinence. Randomised, controlled, superiority trial with two parallel arms. 100 participants with faecal incontinence will be randomised to either (1) individually supervised pelvic floor muscle training and conservative treatment or (2) attention-control massage treatment and conservative treatment. The primary outcome is participants' rating of symptom changes after 16 weeks of treatment using the Patient Global Impression of Improvement Scale. Secondary outcomes are the Vaizey Incontinence Score, the Fecal Incontinence Severity Index, the Fecal Incontinence Quality of Life Scale, a 14-day bowel diary, anorectal manometry and rectal capacity measurements. Follow-up assessment at 36 months will be conducted. This paper describes and discusses the rationale, the methods and in particular the statistical analysis plan of this trial.